Journal Title：Medcomm

MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged. MedComm is interested in topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology and artificial intelligence. The journal focuses on clinical and experimental advances on disease characteristics, pathogenic mechanism and medical techniques.

MedComm是同行評審的在線開放獲取期刊，及時發(fā)表具有新穎性的、對人類健康有重要意義的開創(chuàng)性醫(yī)學(xué)研究。該期刊重視原創(chuàng)性發(fā)現(xiàn)，旨在促進對發(fā)病機制的理解及改善對人類疾病的診斷與治療，尤其青睞利用分子生物學(xué)、細胞生物學(xué)、化學(xué)、藥理學(xué)或材料科學(xué)方法解決臨床、基礎(chǔ)和轉(zhuǎn)化醫(yī)學(xué)問題的跨學(xué)科研究。MedComm關(guān)注的主題包括但不限于臨床醫(yī)學(xué)、分子診斷、表觀遺傳學(xué)/遺傳學(xué)、細胞生物學(xué)、藥物發(fā)現(xiàn)、進化醫(yī)學(xué)、納米技術(shù)和人工智能。該期刊聚焦疾病特征、致病機制和醫(yī)學(xué)技術(shù)的臨床與實驗進展。

Medcomm創(chuàng)刊于2020年，由Wiley出版商出版，收稿方向涵蓋MEDICINE, RESEARCH & EXPERIMENTAL全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 10 Weeks ，影響因子指數(shù)10.7，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。